the aid library

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi ... more

COVID-19 Guidelines Module 5 - Drug therapy

National Department of Health, South Africa NDoH South Africa (2021) CC

Myocarditis and pericarditis after mRNA COVID-19 vaccination in children: Interim guidance

SickKids (2020) CC

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Botswana Essential Drug List (BEDL)

Botswana Essential Drug Action Programme (BEDAP), Ministry of Health, Republic of Botswana (2012) C2

Second Edition, 2012

Safety and monitoring for patients receiving Nirmatrelvir-ritonavir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Notes on the identification, diagnosis and treatment of patients with COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

Liste Nationale des Médicaments et Consommables Medicaux Essentiels Burkina Faso

Ministere de la Sante, Burkina Faso (2020) C_WHO

Liste nationale

Epidemiology of Peripheral Artery Disease and Polyvascular Disease

Aday A.W.; Matsushita, K. Circulation Research (2021) CC

Atherosclerotic lower-extremity peripheral artery disease (PAD) is increasingly recognized as an important cause of cardiovascular morbidity and mortality that affects more than 230 million people worldwide. Traditional cardiovascular risk factors, including advanced age, smoking, and diabetes, are ... more

Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents

Lawrence Flick Memorial Tuberculosis Clinic, Philadelphia Tuberculosis Control Program (1998) C2

COVID-19: Implications for People with Chagas Disease

Zaidel, E.J.; et al. (2020) CC

Glob Heart . 2020 Oct 13;15(1):69. doi: 10.5334/gh.891.

Solomon Islands Essential Medical Supplies List 2017

Sandy Greenwood, Timmy Manea, Willie Horoto et al. National Pharmacy Services Division, Ministry of Health & Medical Services (2017) CC

Solomon Islands pharmacy staff have developed an essential medicines supplies list. It was a collaborative effort involving a lot of staff taking the pictures and putting it all together. The list was launched as an initiative to improve the availability of medical stock within the country

List of Medicines for Ethiopia

Food, Medicine and Healthcare Administration and Control Authority of Ethiopia (2010) C1

6th edition

National List of Essential Medicines for Adults Rwanda 6th edition

Republic of Rwanda, Ministry of Health (2015) C1

The essential medicines are those that meet the priority needs of the healthcare of the population. While reviewing the 5th edition of the essential Medicines, special attention focused on the health sector policy. Indeed, medicines play an important role in protecting, maintaining and restoring th ... more

NEMLIST: Namibia Essential Medicines List

Ministry of Health and Social Services (MOHSS) (2016) C2

NEMLIST | Sixth Edition | February 2016

Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19
recommended

Robert-Koch-Institut RKI (2021) C1

16.7.2021

The 2014 Hepatology Society of the Philippines Consensus Statements on the Diagnosis and Treatment of Hepatitis C

Stephen N. Wong, Jane R. Campos, Ian Homer Y. Cua et al. Hepatology Society of the Philippines (HSP) (2006) C1

Guías de tratamiento farmacológico y manejo de escenarios clínicos de casos de COVID-19

Sociedad Paraguaya de Infectologia (SPI) SPI (2022) C2

Guía de tratamiento farmacológico y manejo deescenarios clínicos de casos de COVID-19 – enero 2022 Guía de tratamiento farmacológico y manejo deLeer más